Clinical Trial Update: Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study [Phase 2]

View source ↗

Summary

Phase 2 trial update for enzalutamide in metastatic or advanced non-resectable granulosa cell ovarian tumors (GREKO III) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)

Snippet

Sponsor: Grupo Español de Tumores Huérfanos e Infrecuentes | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED